A Randomized, Double-Blind, Placebo-Controlled, Dose Response Study to Evaluate 851B Gel Delivered Intravaginally Twice a Week for Two, Three-Week Cycles in Women Who Are Positive For High-Risk Genotypes of Human Papillomavirus and Have Mild Cytological Abnormalities.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Dose Response Study to Evaluate 851B Gel Delivered Intravaginally Twice a Week for Two, Three-Week Cycles in Women Who Are Positive For High-Risk Genotypes of Human Papillomavirus and Have Mild Cytological Abnormalities.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 22 Aug 2016

At a glance

  • Drugs Epetirimod (Primary)
  • Indications Cervical dysplasia; Human papillomavirus infections
  • Focus Therapeutic Use
  • Sponsors 3M Pharmaceuticals; Takeda Global Research and Development Center
  • Most Recent Events

    • 17 Dec 2008 New trial record.
    • 08 Dec 2008 The study was terminated to due to lack of efficacy according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top